Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere
Conditions
Interventions
Intervention1: Virunil 500mg Capsules: 1500mg per day in divided doses (3doses per day) with water.
for up to maximum of 10 days. Mode of Administration: Oral
Control Intervention1: Standard Supporti
Sponsors
NRI ACADEMY OF SCIENCES
Eligibility
Inclusion criteria
Inclusion criteria: Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures. Patient who are present in the stages of 1 and 2 of the COVID-19 disease.
Exclusion criteria
Exclusion criteria: 1. Patients with Auto Immune Disorders. 2. Patients with Co morbid conditions such as Diabetes Mellitus and Hypertension. 3. Patients Under any kind of Anti-Cancer medication, Immunosuppressants. 4. Patients who are under anti-platelet medication. 5. Patients with history of Organ Transplantation. 6. Patients with compromised pulmonary function. 7. Patients receiving antiviral drugs. 8. Pregnant and lactating mothers are also excluded from the study. 9. Any other condition, where investigators jeopardize the outcomes of the trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The drug may reduce the hospital stay & inflammatory condition of COVID19 patientsTimepoint: At base line, 7th day and 10th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Time from randomization to first time use of high flow supplemental oxygen/non-invasive ventilation/mechanical ventilation/ extracorporeal membrane oxygenationTimepoint: Randomization to hospital discharge (or day 28, which ever is earlier) | — |
Countries
India
Contacts
Public ContactDr V Siva Prabodh
N R I MEDICAL COLLEGE AND GENERAL HOSPITAL
Outcome results
None listed